PCT Ltd (PCTL)

[Long term]

This is great..Pctl on sale...update 4/24/2020 DD & links & for U.K. & CANADA Consolidated

PCT Europe LTD Signs Distribution Agreement With UK NHS Company, Receives Additional NYC Hospital Order

PCT LTD Discusses Its Rapid Growth and Expansion Plans with The Stock Day Podcast
https://audioboom.com/posts/7562220-pct-ltd-discusses-its-rapid-growth-and-expansion-plans-with-the-stock-day-podcast

LINK:
https://finance.yahoo.com/news/pct-europe-ltd-signs-distribution-200000409.html

PCTL on 2 TV BROADCAST Networks. Plus Fully current !
TOMORROW should be VERY EXTREMELY exciting !

https://www.wmbfnews.com/video/2020/04/15/little-river-company-makes-hospital-cleaning-supplies/

https://www.myrtlebeachonline.com/latest-news/article242029616.html

ACTION NEEDED Pctl has been trying to get in contact with the government to make them aware of our machine & what it can do
We can help with & in our numbers send them copies of the DD that’s been posted

This is the contact point in government that needs to know about pctl Paradigm Convergence Technology. (Read below)

https://www.medicalcountermeasures.gov/Request-BARDA-TechWatch-Meeting/


See how it works - https://lnkd.in/eacqr7x

My VP of nyc hospital attests to how good our machine works

https://www.linkedin.com/search/results/content/?facetSortBy=date_posted&keywords=Jonathan%20Johonnesson&origin=GLOBAL_SEARCH_HEADER


Info they’ll need:
PODCAST LINK click
Click in search....Pctl

This is who we can contact in government to make them aware of our machine.

point of entry for the submission of market research packages and meeting requests from interested stakeholders.
The U.S. government, in response to the COVID-19 outbreak, seeks information from stakeholders on available medical countermeasures in development. We are particularly interested in products and technologies that have progressed into or beyond non-clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products or technologies relevant to addressing this outbreak are sought.
At this time, we ask for a brief description of your product or technology, accompanied by a slide deck, manuscript, publications, or other non-confidential information of your choosing. Please note that while we will use any information you present as market research, submission is no guarantee of a meeting or funding and your submission will be shared across U.S. Government agencies involved in COVID-19 medical countermeasure research and development.  Only U.S. government officials are invited to join a CoronaWatch meeting, and are bound by law to maintain confidentiality of what is presented and discussed.
Ideal technologies and products would (but are not required to) be:
* - Relevant to the U.S. government COVID-19 medical countermeasure research and development efforts and/or Emerging .Infectious Disease rapid response capabilities
* - Utilize an already-approved platform, have non-clinical data suggesting efficacy, and/or have significant manufacturing capability
* - Fully owned or licensed by your organization (you have full IP rights and/or freedom to operate)
 
Would you like to meet with a federal agency regarding a product that you are developing for COVID-19?
If you are interested in requesting a CoronaWatch meeting, please Register for an account and Login, or if you have an account Login to submit some basic product information.

Select A portion of this DD ( below dotted line)& send to government site
https://www.medicalcountermeasures.gov/Request-BARDA-TechWatch-Meeting/

PR/heightened demand: https://www.businesswire.com/news/home/20200313005307/en/

Annihilyzer™ system: https://www.youtube.com/watch?v=bZLjJdqpz9s&feature=youtu.be

Paradigm Convergence Technologies Corporation
Summarized Due Diligence Sheet for Investing
[color=red]

ACTION NEEDEDPctl has been trying to get in contact with the government to make them aware of our machine & what it can do
We can help with & in our numbers send them copies of the DD that’s been


This is the contact point in government that needs to know about pctl Paradigm Convergence Technology. (Read below)

https://www.medicalcountermeasures.gov/Request-BARDA-TechWatch-Meeting/



Info they’ll need:

PODCAST LINK click
Click in search....Pctl


Much more DD below dotted line

This is who we can contact in government to make them aware of our machine.

point of entry for the submission of market research packages and meeting requests from interested stakeholders.
The U.S. government, in response to the COVID-19 outbreak, seeks information from stakeholders on available medical countermeasures in development. We are particularly interested in products and technologies that have progressed into or beyond non-clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products or technologies relevant to addressing this outbreak are sought.
At this time, we ask for a brief description of your product or technology, accompanied by a slide deck, manuscript, publications, or other non-confidential information of your choosing. Please note that while we will use any information you present as market research, submission is no guarantee of a meeting or funding and your submission will be shared across U.S. Government agencies involved in COVID-19 medical countermeasure research and development. Only U.S. government officials are invited to join a CoronaWatch meeting, and are bound by law to maintain confidentiality of what is presented and discussed.
Ideal technologies and products would (but are not required to) be:
* - Relevant to the U.S. government COVID-19 medical countermeasure research and development efforts and/or Emerging .Infectious Disease rapid response capabilities
* - Utilize an already-approved platform, have non-clinical data suggesting efficacy, and/or have significant manufacturing capability
* - Fully owned or licensed by your organization (you have full IP rights and/or freedom to operate)

Would you like to meet with a federal agency regarding a product that you are developing for COVID-19?
If you are interested in requesting a CoronaWatch meeting, please Register for an account and Login, or if you have an account Login to submit some basic product information.

===================================================


--GENERAL INFORMATION---

Company Site: para-con.com
Twitter: @PCTL2020
Investor Relations Chesapeake Group - Get on the email list for news [e-mail]

About: a technology licensing company specializing in environmentally safe solutions for global sustainability with products for various markets they serve.

Mission: Infectious Disease and Contamination Control

Markets Served: Hospitals & Healthcare, Agriculture, Oil & Gas, Hotel & Tourism, Food Service/Production

About Products: Products and solutions are designed to take an environmentally conscious approach to combating the spread of infectious disease in the Healthcare and Cleaning industries, as well as contributing to the sustainability of global natural resources in the energy and agriculture markets.

The PCT Annihilyzer® Patented Monitoring, Tracking & Reporting System
The Kiosk, which sits on top of the Filling Station Cabinet, houses The PCT Annihilyzer® System’s computer controls, information system, RFID tagging and reading system and an interactive touch screen display.


---FINANCIAL INFO---

Filings: LINK

Current info as of 3/9/20
Authorized- 1,000,000,000
Outstanding- 511,315,300
Restricted- 35,139,690

Standard Registrar and Transfer Company
440 East 400 South, Suite 200
Salt Lake City, UT 84111
Phone: [phone] or 801-596-2150
www.standardtransferco.com
Amy Merrill Email: [e-mail]


---CURRENT CLIENT LIST---

1: Morgan Stanley Presbyterian Children’s Hospital.
(3959 Broadway At, W 165 St, New York NY 10032)

2: Mount Sinai South Nassau Hospital
(1 Healthy Way, Oceanside NY 11572)

3: Carson Tahoe Regional Medical Center
(1600 Medical Pkwy, Carson City NV 89703)

4: SUNY Downstate Medical Center
(450 Clarkson Ave, Brooklyn NY 11203)

5: Johnston UNC Healthcare Hospital Smithfield
(509 N Brightleaf Blvd , Smithfield, NC 27577)

6: Memorial Sloan Kettering Cancer Center ??? Maybe
(1275 York Avenue New York, NY 10065)

7: North Tees and Hartlepool NHS Foundation Trust, (UK Trial underway began Jan 15th 2020 - 60 day trial)
(University Hospital of Hartlepool, Holdforth Road, Hartlepool, TS24 9AH)
(University Hospital of North Tees, Hardwick, Stockton on Tees, TS19 8PE)

8: New York Presbyterian Columbia Hospital
(Ranked Top 5 in the Nation)
(622 W 168th St, New York NY 10032)
---VP recently endorsed in a LinkedIn post---

9: New York Hospital -- as per PR Release (labeled #1 below)

---PR & RELATED INFORMATION---


1. 03/11/20 - PCT LTD Experiencing Rapid Increase in Interest and Receives Purchase Order from Additional Hospital in New York City PR LINK

2. 03/09/20 - Interview: PCT LTD Hospital Infection Control System installed in seven hospitals and expanding INTERVIEW LINK

3. 02/14/20 - PCT LTD Schedules Investor Call (Call took place on 2/20/20) PR LINK Audio Link (Written Summation below)

4. 01/30/20 - PCT LTD Executes Term Sheet for Debt Financing PR LINK

5. 01/08/20 - PCT LTD Discusses Their International Expansion and Growth Strategy with The Stock Day Podcast PR LINK

6. 12/16/19 - PCT LTD Issues Company Update and Signs Collaborative Agreement for Oil & Gas, and Cannabis Applications PR LINK

7. 10/31/19 - PCT LTD Continues to Expand By Signing Agreement with SUNY Downstate Medical Center Worth over $500,000 PR LINK

8. 10/25/19 - 3rd Quarter 8K released (see above FILINGS link)

9. 10/22/19 - Hospital-acquired Infection Control Market Is Estimated To Expand At a Healthy CAGR in the Upcoming Forecast Period MARKET RESEARCH PR

10. 10/22/19 - PCT LTD Deploys Initial Annihilyzer(R) Infection Control System to the United Kingdom PR LINK

11. 10/4/19 - PCT LTD Announces Additional Hospital Installation of Annihilyzer(R) Infection Control System PR LINK

12. 7/26/19 - The Infection Prevention Strategy is pleased to announce our Top Innovations of the Year: 2019 (Annihilyzer) PR LINK

13. 5/6/2019 - PCT LTD Announces New Purchase Order as the Result of a Successful Trial of Annihilyzer® Infection Control Systems (A TOP 5 hospital in the U.S. AND --#1 in NY-- CONVERTED from Trial to a customer AFTER a successful trial period) - Morgan Stanley Presbyterian Children’s Hospital PR LINK

14. 2/25/19 - PCT LTD Installs a Large Volume Hydrolyte® System with Option Agreement for 4 additional LVH Systems with Oil & Gas Industry Customer PR LINK

15. 1/10/19 - PCT LTD Executes New Master Service Agreement for Installation of Annihilyzer® Hospital Infection Control System at Carson Tahoe Regional Medical Center PR LINK

16. 11/08/18 - PCT LTD Announces Completion of Major Commercialization Milestones and Promotion of Jody Read to CEO Position PR LINK

17. 5/16/18 - Newly Launched Disinfecting System Reduces Hospital Acquired Infections PR LINK

18. 5/10/18 - PCT LTD Receives Patents for RFID Tracking Technology in Cleaning System (US Patent#9679170) PR LINK



----Investor Call Summation, Paradigm Convergeance Technologies Corporation----
---First 10 minutes of call---

---Addressing Financial Filings---

3rd Quarter 10Q
In final review with auditors & SEC Attorneys
Expected to be completed in up to 3 weeks
(updated per IR email--- expected in the next week)

10K
Expected to be filed by April 13th

Convertible Notes
"very active negotiations" to come to a resolve by time of 10K filing (April 13th)

No material change is O/S in months

very actively negotiating financing with negligible, if any, dissolution
No anticipation of R/S

---Growth of about 400% in 2019---
on target to grow exponentially in 2020

G&A down significantly
company become more efficicent, losses narrowed significantly down around 75% from 2018

---Currently Doing---

PCT UK joint venture partner
Trial ongoing: Universities as well as hospitals involved to verify U.S. results
"unless bacteria and virsuses are any different, which they aren't, don't anticipate any difficulty verifying claims"

"Preliminary discussions between PCT UK and National Healthcare system of the UK"

---Markets---
Primary Focus on healthcare sector - hospitals, medical centers assisted living, rehab facilities

Secondarily - Oil & Gas, remediation of Hydrogen Sulfide (very poisonous, corrosive, and flammable)

Recently - Cannabis Industry - purveyor of service
"Happy to discover our product greatly mitigates or totally eliminates the 3 major problems they are having"

---Current Placement--- (Does not include newest NY Hospital announced above in PR on 3/11/20)
8 hospitals, 11 units installed with "3 more slated in next few weeks with more behind it"


Endorsement from VP of MY Presbyterian
[Suppressed Image]


Not sure how many are aware of BARDA, but I came across a post on Twitter this evening and after doing a little digging, found this:

Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, was established to aid in securing our nation from chemical, biological, radiological, and nuclear (CBRN) threats, as well as from pandemic influenza (PI) and emerging infectious diseases (EID).

In my eyes that's most certainly an organization that should be aware of the Annihilyzer product, so I connected with their Director, Rick B and provided a post on Linkedin for more exposure to their request of building out a comprehensive portfolio of COVID-19 countermeasures. See below.

(For my privacy, I did redact my information on the image)

Post made to BARDA Director, Deputy Assistant Secretary for Preparedness & Response - U.S. Department of Health & Human Services

[Suppressed Image]

Post made to BARDA Director, Deputy Assistant Secretary for Preparedness & Response - U.S. Department of Health & Human Services


UPDATED DUE DILIGENCE 3-17 - RESEARCH NOW
Below is a good portion of the DD done here, by myself and others. Do YOURS now!
(Also pinned on top of board)

Paradigm Convergence Technologies Corporation
Summarized Due Diligence Sheet for Investing


---GENERAL INFORMATION---

Company Site: para-con.com
Twitter: @PCTL2020 - (I urge you to follow them and review their posts)
Investor Relations Chesapeake Group - Get on the email list for news [e-mail]

About: a technology licensing company specializing in environmentally safe solutions for global sustainability with products for various markets they serve.

Mission: Infectious Disease and Contamination Control

Markets Served: Hospitals & Healthcare, Agriculture, Oil & Gas, Hotel & Tourism, Food Service/Production

About Products: Products and solutions are designed to take an environmentally conscious approach to combating the spread of infectious disease in the Healthcare and Cleaning industries, as well as contributing to the sustainability of global natural resources in the energy and agriculture markets.

The PCT Annihilyzer® Patented Monitoring, Tracking & Reporting System
The Kiosk, which sits on top of the Filling Station Cabinet, houses The PCT Annihilyzer® System’s computer controls, information system, RFID tagging and reading system and an interactive touch screen display.


---FINANCIAL INFO---

Filings: LINK

Current info as of 3/9/20
Authorized- 1,000,000,000
Outstanding- 511,315,300
Restricted- 35,139,690

Standard Registrar and Transfer Company
440 East 400 South, Suite 200
Salt Lake City, UT 84111
Phone: [phone] or 801-596-2150
www.standardtransferco.com
Amy Merrill Email: [e-mail]

---CURRENT CLIENT LIST---

1: Morgan Stanley Presbyterian Children’s Hospital.
(3959 Broadway At, W 165 St, New York NY 10032)

2: Mount Sinai South Nassau Hospital
(1 Healthy Way, Oceanside NY 11572)

3: Carson Tahoe Regional Medical Center
(1600 Medical Pkwy, Carson City NV 89703)

4: SUNY Downstate Medical Center
(450 Clarkson Ave, Brooklyn NY 11203)

5: Johnston UNC Healthcare Hospital Smithfield
(509 N Brightleaf Blvd , Smithfield, NC 27577)

6: Memorial Sloan Kettering Cancer Center ??? Maybe
(1275 York Avenue New York, NY 10065)

7: North Tees and Hartlepool NHS Foundation Trust, (UK Trial underway began Jan 15th 2020 - 60 day trial)
(University Hospital of Hartlepool, Holdforth Road, Hartlepool, TS24 9AH)
(University Hospital of North Tees, Hardwick, Stockton on Tees, TS19 8PE)

8: New York Presbyterian Columbia Hospital
(Ranked Top 5 in the Nation)
(622 W 168th St, New York NY 10032)
---VP recently endorsed in a LinkedIn post---

9: New York Hospital -- as per PR Release (labeled #1 below)

---PR & RELATED INFORMATION---

1. 03/18/20 - PCT LTD Receives Large Purchase Order for Recurring Sales of Fluids for Non-Medical Use and Explains Current Revenue Streams PR LINK

2. 03/16/20 - PCT LTD Interview with Stock Day Podcast (MUST LISTEN) PR LINK

3. 03/13/20 - PCT LTD Adds International Distributor and Sells High-Volume Equipment to Existing Customer as a Result of Heightened Demand PR LINK

4. 03/11/20 - PCT LTD Experiencing Rapid Increase in Interest and Receives Purchase Order from Additional Hospital in New York City PR LINK

5. 03/09/20 - Interview: PCT LTD Hospital Infection Control System installed in seven hospitals and expanding INTERVIEW LINK

6. 02/14/20 - PCT LTD Schedules Investor Call (Call took place on 2/20/20) PR LINK Audio Link (Written Summation below)

7. 01/30/20 - PCT LTD Executes Term Sheet for Debt Financing PR LINK

8. 01/08/20 - PCT LTD Discusses Their International Expansion and Growth Strategy with The Stock Day Podcast PR LINK

9. 12/16/19 - PCT LTD Issues Company Update and Signs Collaborative Agreement for Oil & Gas, and Cannabis Applications PR LINK

10. 10/31/19 - PCT LTD Continues to Expand By Signing Agreement with SUNY Downstate Medical Center Worth over $500,000 PR LINK

11. 10/25/19 - 3rd Quarter 8K released (see above FILINGS link)

12. 10/22/19 - Hospital-acquired Infection Control Market Is Estimated To Expand At a Healthy CAGR in the Upcoming Forecast Period MARKET RESEARCH PR

13. 10/22/19 - PCT LTD Deploys Initial Annihilyzer(R) Infection Control System to the United Kingdom PR LINK

14. 10/4/19 - PCT LTD Announces Additional Hospital Installation of Annihilyzer(R) Infection Control System PR LINK

15. 7/26/19 - The Infection Prevention Strategy is pleased to announce our Top Innovations of the Year: 2019 (Annihilyzer) PR LINK

16. 5/6/2019 - PCT LTD Announces New Purchase Order as the Result of a Successful Trial of Annihilyzer® Infection Control Systems (A TOP 5 hospital in the U.S. AND --#1 in NY-- CONVERTED from Trial to a customer AFTER a successful trial period) - Morgan Stanley Presbyterian Children’s Hospital PR LINK

17. 2/25/19 - PCT LTD Installs a Large Volume Hydrolyte® System with Option Agreement for 4 additional LVH Systems with Oil & Gas Industry Customer PR LINK

18. 1/10/19 - PCT LTD Executes New Master Service Agreement for Installation of Annihilyzer® Hospital Infection Control System at Carson Tahoe Regional Medical Center PR LINK

19. 11/08/18 - PCT LTD Announces Completion of Major Commercialization Milestones and Promotion of Jody Read to CEO Position PR LINK

20. 5/16/18 - Newly Launched Disinfecting System Reduces Hospital Acquired Infections PR LINK

21. 5/10/18 - PCT LTD Receives Patents for RFID Tracking Technology in Cleaning System (US Patent#9679170) PR LINK

----Investor Call Summation, Paradigm Convergeance Technologies Corporation----
---First 10 minutes of call---

---Addressing Financial Filings---

3rd Quarter 10Q
In final review with auditors & SEC Attorneys
Expected to be completed in up to 3 weeks
(updated per IR email--- expected in the next week)

10K
Expected to be filed by April 13th

Convertible Notes
"very active negotiations" to come to a resolve by time of 10K filing (April 13th)

No material change is O/S in months

very actively negotiating financing with negligible, if any, dissolution
No anticipation of R/S

---Growth of about 400% in 2019---
on target to grow exponentially in 2020

G&A down significantly
company become more efficicent, losses narrowed significantly down around 75% from 2018

---Currently Doing---

PCT UK joint venture partner
Trial ongoing: Universities as well as hospitals involved to verify U.S. results
"unless bacteria and virsuses are any different, which they aren't, don't anticipate any difficulty verifying claims"

"Preliminary discussions between PCT UK and National Healthcare system of the UK"

---Markets---
Primary Focus on healthcare sector - hospitals, medical centers assisted living, rehab facilities

Secondarily - Oil & Gas, remidiation of Hydrogen Sulfide (very poisonous, corrosive, and flammable)

Recently - Cannabis Industry - purveyor of service
"Happy to discover our product greatly mitigates or totally elimiants the 3 major problems they are having"

---Current Placement--- (Does not include newest NY Hospital announced above in PR on 3/11/20)
8 hospitals, 11 units installed with "3 more slated in next few weeks with more behind it"


Endorsement from VP of MY Presbyterian and other execs
[Suppressed Image]

[Suppressed Image]

[Suppressed Image]

[Suppressed Image]


Not sure how many are aware of BARDA, but I came across a post on Twitter this evening and after doing a little digging, found this:

Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, was established to aid in securing our nation from chemical, biological, radiological, and nuclear (CBRN) threats, as well as from pandemic influenza (PI) and emerging infectious diseases (EID).

In my eyes that's most certainly an organization that should be aware of the Annihilyzer product, so I connected with their Director, Rick B and provided a post on Linkedin for more exposure to their request of building out a. comprehensive portfolio of COVID-19 countermeasures. See below.

(For my privacy, I did redact my information on the image)

Post made to BARDA Director, Deputy Assistant Secretary for Preparedness & Response - U.S. Department of Health & Human Services

=================
exactly what the EPA said

Quote:

List N includes products that meet EPA’s criteria for use against SARS-CoV-2, the novel coronavirus that causes the disease COVID-19.

The key word here is against The EPA does not come out and say any products on these lists will kill CV-19. However I doubt the EPA would use a strong word as against in the above statement.

Quote:

Note: Inclusion on this list does not constitute an endorsement by EPA. There may be additional disinfectants that meet the criteria for use against SARS-CoV-2. EPA will update this list with additional products as needed.



It's pretty obvious this disclaimer is stating the EPA does not endorse as in recommend any product that's listed. They do not because it would constitute marketing for that product.... The EPA also recognizes that there are other products that meet the criteria against SARS-CV-2 AKA Coronavirus. Why do they make this statement? Because there are other products that are registered with the EPA that are not on this list that meets the criteria against CV-19

Nothing hard to understand there. Here is the a pic of it below:

[Suppressed Image]


Lets move on

List N: Disinfectants for Use Against SARS-CoV-2 | Pesticide ...www.epa.gov › pesticide-registration › list-n-disinfectants-use-against-...
If a product qualified for the Emerging Viral Pathogen Claim, it demonstrated efficacy against a harder-to-kill virus than the enveloped human coronavirus

From this statement we know that EXCELYTE which meets this criteria. How do we know this? We know because they are on the N list under EPA registration 92108-1. I also believe this Reg number can be used against the harder to lill Norovirus. Coronavirus is easier to kill than Norovirus. Any amount of basic DD will show that.

Below is the reg and product number for EXCELYTE
[Suppressed Image]

Finally Below is the EPA reg link for EXCELYTE showing it's registered to PCT Ltd. This link is the original registration.

https://iaspub.epa.gov/apex/pesticides/f?p=PPLS:8:1272595636521::NO::P8_PUID,P8_RINUM:513158,92108-1


To wrap it all up is the link to the current N list


https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2


Pretty basic stuff is you ask me lol
==============
Pics of the product - Sorry about it being sideways

[Suppressed Image]

[Suppressed Image]

[Suppressed Image]

============
PCT LTD Obtains EPA Approval for Emerging Pathogens Labeling for Use Against SARS-CoV-2, the Novel Coronavirus That Causes the Disease COVID-19
Business WireMarch 27, 2020, 9:49 AM CST

PCT LTD (OTC Pink: PCTL) ("PCTL") is pleased to announce that it has received approval for "emerging pathogens" labeling with the US EPA.

The application was filed under the guidance document "Guidance to Registrants: Process for Making Claims Against Emerging Viral Pathogens Not on EPA-Registered Disinfectant Labels." It was approved on March 26th, 2020. The guidance document provides the following information regarding different classes of viruses and their resistance to being killed by disinfectants:

EPA and the Centers for Disease Control and Prevention (CDC) recognize that certain microorganisms can be ranked with respect to their tolerance to chemical disinfectants. The Spaulding Classification model, used by CDC, tiers microorganisms in accordance with the level of resistance to being killed (inactivation) by typical disinfectant products. With this approach viruses are divided into three viral subgroups (small non-enveloped, large non-enveloped, and enveloped) based on their relative resistance to inactivation … According to this hierarchy, if an antimicrobial product can kill a small, non-enveloped virus it should be able to kill any large, non-enveloped virus or any enveloped virus. Similarly, a product that can kill a large, non-enveloped virus should be able to kill any enveloped virus.


Small, Non-Enveloped Viruses (<50 nm): These small, non-enveloped viruses can be highly resistant to inactivation by disinfection. Despite the lack of a lipid envelope, these organisms have a very resistant protein capsid…

Large, Non-Enveloped Viruses: Compared to small, non-enveloped viruses, these viruses are less resistant to inactivation by disinfection. Although they have a resistant protein capsid, their larger size (50-100nm) makes them more vulnerable than their smaller viral counterparts…

Enveloped Viruses: Enveloped viruses are the least resistant to inactivation by disinfection. The structure of these viruses includes a lipid envelope, which is easily compromised by most disinfectants. Once the lipid envelope is damaged, the integrity of the virus is compromised, thereby neutralizing its infectivity.

In addition to being "an EPA-registered, hospital/healthcare or broad-spectrum disinfectant …", in order to meet product eligibility criteria, the product "should have disinfectant efficacy claims against at least one of the following viral pathogen groupings:

a) A product should be approved by EPA to inactivate at least one large or one small non-enveloped virus to be eligible for use against an enveloped emerging viral pathogen.

b) A product should be approved by EPA to inactivate at least one small, non-enveloped virus to be eligible for use against a large, non-enveloped emerging viral pathogen.

c) A product should be approved by EPA to inactivate at least two small, non-enveloped viruses with each from a different viral family to be eligible for use against a small, non-enveloped emerging viral pathogen.

This approach, where disinfectant products registered for use against viral pathogens in one category of the Spaulding Classification model can be presumed effective against viral pathogens in less-resistant categories, is intended to serve as a conservative approach to identifying disinfectant products likely to be effective against emerging pathogens."

As a result of meeting all of the Product Eligibility Criteria, PCT LTD can now make the following statement "only through the following communication outlets: … "1-800" consumer information services, social media sites and company websites (non-label related) … [as well as] technical literature distributed exclusively to health care facilities, physicians, nurses and public health officials":

This Product meets the criteria to make claims against certain emerging viral pathogens from the following viral category[ies]:

Enveloped Viruses

Large Non-Enveloped Viruses

Small Non-Enveloped Viruses


For an emerging viral pathogen that is a/an…
…follow the directions for use for the following organisms on the label:
Enveloped virus
Norovirus
Large, non-enveloped virus
Norovirus
Small, non-enveloped virus
Norovirus, Rhinovirus (Type 16)

Hydrolyte® has demonstrated effectiveness against viruses similar to SARS-CoV-2 virus on hard, non-porous surfaces. Therefore, Hydrolyte® can be used against SARS-CoV-2 virus when used in accordance with the directions for use against Norovirus and Rhinovirus type 16 on hard, non-porous surfaces. Refer to the CDC website at https://www.cdc.gov/coronavirus/2019-ncov/community/home/cleaning-disinfection.html for additional information.

COVID-19 is caused by SARS-CoV-2 virus. Hydrolyte® kills similar viruses and therefore can be used against SARS-CoV-2 virus when used in accordance with the directions for use against Norovirus and Rhinovirus type 16 on hard, non-porous surfaces. Refer to the CDC website at https://www.cdc.gov/coronavirus/2019-ncov/community/home/cleaning-disinfection.html for additional information.

"We are very pleased to receive approval for an "emerging pathogens" claim on our product label," says CEO Gary Grieco. "It represents an important step for us as a business and in helping to control the spread of infectious disease as a whole. Additionally, we are now prequalified for future emerging pathogens of any virus classification."

Due to the ongoing coronavirus pandemic, PCT LTD has seen an increased number of inquiries from existing clients, sub-registrants, and distributors; in addition to new and prospective customers. The company recently announced that they had temporarily shifted their focus towards producing mass quantities of disinfecting fluids to meet growing demand.

"Fluid sales have been tremendous for us," says PCT Ltd CEO Gary Grieco. "To put it simply, we are routinely shipping fluids out at rapid pace and into the hands of trained professionals where our product can be put to good use fighting the spread of infectious disease in our communities. We are limited only by our capacity to produce the fluids, but we expect to double our production capacity by April 1st."

Additional News and Corporate Updates:

PCTL would like to warn its stockholders and potential investors that material corporate information regarding sales, areas of business and other corporate updates will only be made through press releases or filings with the SEC. PCTL does not utilize social media, chatrooms or other online sources to disclose material information. The public should only rely on official press releases and corporate filings for accurate and up to date information regarding PCTL.

About PCT LTD:

PCT LTD ("PCTL") focuses its business on acquiring, developing and providing sustainable, environmentally safe disinfecting, cleaning and tracking technologies. The company acquires and holds rights to innovative products and technologies, which are commercialized through its wholly-owned operating subsidiary, Paradigm Convergence Technologies Corporation (PCT Corp). Currently trading on OTC, "PCTL" aspires to and is actively engaged in preparations for up-listing its common stock to a national securities exchange. The Company established entry into its target markets with commercially viable products in the United States and now continues to gain market share in the U.S. and U.K.

Forward-Looking Statements:

This press release contains "forward-looking statements" as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21B of the Securities Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward-looking statements."

Such statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Such statements involve risks and uncertainties, including but not limited to: the impact of having met the EPA Criteria for use Against SARS-CoV-2, actual sales derived by the Company; the transition to producing large quantities of fluids; PCTL's and its subsidiary's business prospects; PCTL's ability to raise sufficient funds to satisfy its working capital requirements; the ability of PCTL to execute its business plan; any other effects resulting from the information disclosed above; risks and effects of legal and administrative proceedings and government regulation; future financial and operational results; competition; general economic conditions; and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements PCTL makes in this press release include market conditions and those set forth in reports or documents it files from time to time with the SEC. PCTL undertakes no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200327005363/en/

Contacts

Gary Grieco, CEO and Chairman, PCT LTD
[phone] Office
[phone] Fax
www.para-con.com
www.pctcorphealth.com
www.survivalyte.com

Brokers and Analysts: Chesapeake Group
[phone]
[e-mail]
==================================================================================================================. CANADA INFO & LINKS
BokehRebl  
Tuesday, 03/31/20 10:29:25 PM
Re: Long term post# 78282
?
0
Post # 78283 of 78339 

Here’s THE list I put together of all relevant contact in the US and Canadien Government, Feel free to add more!

USA Counter Measures
https://www.medicalcountermeasures.gov/Request-BARDA-TechWatch-Meeting/

Canada calling all suppliers
https://buyandsell.gc.ca/calling-all-suppliers-help-canada-combat-covid-19


Health ministers of Canada
Patty Hardy
[e-mail]

————————————————

Health minister of Quebec
Danielle McCann
[e-mail]
[e-mail]

Health minister of Ontario
Christine Elliott
[e-mail]

Health minister of British Columbia
Adrian Dix
[e-mail]

Health Minister of Alberta
Tyler Shandro
[e-mail]
Jason Luan
[e-mail]

Health Minister of Saskatchewan
Jim Reiter
[e-mail]

Health Minister of Manitoba
Cameron Frysien
[e-mail]

Others for Canada

Chief Public Health Officer of Canada
Twitter @CPHO_Canada
Dr. Theresa Tam

[e-mail]
[e-mail]
general email


Health Commissioners USA


Alabama
Scott Harris, MD, MPH [Bio]
State Health Officer
[e-mail]

Alaska
Anne Zink, MD, FACEP*
Chief Medical Officer
[e-mail]

Arizona
Cara M. Christ, MD, MS [Bio]
Director and State Health Official
[e-mail]

Arkansas
Nathaniel H. Smith, MD, MPH [Bio]
Director and State Health Officer
[e-mail]

California
Sonia Angell, MD, MPH
Director, Department of Public Health
[e-mail]

Colorado
Jill Ryan, MPH [Bio]
Executive Director
[e-mail]

Commonwealth of Northern Mariana Islands
Esther L. Muña, MHA, FACHE [Bio]
CEO, Commonwealth Healthcare Corporation
[e-mail]

Connecticut
Renee Coleman-Mitchell, MPH [Bio]
Commissioner\
[e-mail]


Delaware
Karyl Rattay, MD, MS [Bio]
Director, Division of Public Health
[e-mail]


District of Columbia
LaQuandra S. Nesbitt, MD, MPH [Bio]
Director
[e-mail]

Florida
Scott Rivkees, MD
State Surgeon General
[e-mail]
[e-mail]

Georgia
Kathleen Toomey, MD, MPH [Bio]
Commissioner, Director of Health Protection
[e-mail]

Guam
Linda Unpingco-DeNorcey, MPH [Bio]
Director, Department of Public Health and Social Services
[e-mail]

Hawaii
Bruce S. Anderson, PhD [Bio]
Director of Health
[e-mail]

Idaho
Elke Shaw-Tulloch, MHS [Bio]
Public Health Administrator
[e-mail]

Illinois
Ngozi Ezike, MD [Bio]
Director of Public Health
[e-mail]

Indiana
Kristina M. Box, MD [Bio]
State Health Commissioner
[e-mail]

Iowa
Gerd W. Clabaugh, MPA [Bio]
Director
[e-mail]

Kansas
Lee Norman, MD, MHS, MBA*
Secretary
[e-mail]

Kentucky
Angela Dearinger, MD, MPH*
Commissioner
[e-mail]

Louisiana
Alexander Billioux, MD, DPhil [Bio]
Assistant Secretary of Health
[e-mail]

Maine
Nirav Shah, MD, JD*
Director, Maine Center for Disease Control and Prevention
[e-mail]

Maryland
Robert Neall
Secretary of Health
Frances B. Phillips, RN, MHA [Bio]
Deputy Secretary for Public Health Services
S/THO Designee
[e-mail]

Massachusetts
Monica Bharel, MD, MPH [Bio]
Commissioner
[e-mail]

Michigan
Joneigh Khaldun, MD, MPH, FACEP [Bio]
Chief Deputy Director for Health and CME
[e-mail]

Minnesota
Jan Malcolm [Bio]
Health Commissioner
[e-mail]

Mississippi
Thomas Dobbs, MD, MPH*
State Health Officer
[e-mail]

Missouri
Randall W. Williams, MD, FACOG [Bio]
Director
[e-mail]

Montana
Sheila Hogan
Director
Gregory Holzman, MD [Bio]
Chief Medical Officer
S/THO Designee
[e-mail]

Nebraska
Dannette Smith, MSW *
Chief Executive Officer, Nebraska Department of Health & Human Services
Gary Anthone, MD
Chief Medical Officer and Director, Division of Public Health
S/THO Designee
[e-mail]

Nevada
Lisa Sherych, MBA*
Administrator
[e-mail]

New Hampshire
Lisa Morris, MSSW [Bio]
Director, Division of Public Health Service
[e-mail]

New Jersey
Judith Persichilli RN, BSN, MA*
Commissioner of Health
[e-mail]

New Mexico
Kathy Kunkel, JD, MSW [Bio]
Cabinet Secretary Designee
Abinash Achrekar, MD
Deputy Secretary
S/THO Designee
[e-mail]

New York
Howard Zucker, MD, JD [Bio]
Commissioner of Health
[e-mail]

North Carolina
Mark Benton [Bio]
Assistant Secretary for Public Health
[e-mail]


North Dakota
Mylynn K. Tufte, MBA, MSIM, RN [Bio]
State Health Officer
[e-mail]

Ohio
Amy Acton, MD, MPH [Bio]
Director of Health
[e-mail]

Oklahoma
Gary Cox, JD*
Commissioner of Health
[e-mail]

Oregon
Lillian M. Shirley, BSN, MPH, MPA [Bio]
Public Health Director
[e-mail]

Pennsylvania
Rachel Levine, MD [Bio]
Secretary of Health
[e-mail]

Puerto Rico
Rafael Rodriguez Mercado, MD, FACS, FAANS
Secretary of Health
Catherine De La Cruz-Duran*
S/THO Designee
[e-mail]

Rhode Island
Nicole Alexander-Scott, MD, MPH [Bio]
Director
[e-mail]

South Carolina
Richard Toomey, MHA, DHA [Bio]
Director, South Carolina Department of Health and Environmental Control
[e-mail]

South Dakota
Kim Malsam-Rysdon [Bio]
Secretary
[e-mail]

Tennessee
Lisa Piercey MD, MBA, FAAP [Bio]
Commissioner
[e-mail]

Texas
John Hellerstedt, MD [Bio]
Commissioner
[e-mail]

Utah
Joseph Miner, MD [Bio]
Executive Director
[e-mail]

Vermont
Mark Levine, MD [Bio]
Commissioner of Health 
[e-mail]

Virginia
M. Norman Oliver, MD, MA [Bio]
State Health Commissioner
[e-mail]

Washington
John M. Wiesman, DrPH, MPH [Bio]
Secretary of Health
[e-mail]

West Virginia
Cathy Slemp, MD, MPH [Bio]
Commissioner and State Health Officer
[e-mail]

Wisconsin
Jeanne Ayers, RN, MPH [Bio]
Administrator, Division of Public Health
[e-mail]

Wyoming 
Alexia Harrist, MD, PhD [Bio]
State Health Officer
[e-mail]
—————————————

davidsan Wednesday, April 1, 2020 4:57:18 PM
Re: None Post # 78774 of 78834
Can PCTL's fluid turn sour crude oil into sweet?

I vaguely remember this was something said in discussing why that large unnamed oil&gas company was so interested in setting up the customized trial they are doing. I remember clearly that it helped make the liquid involved in fracking much more environmentally friendly, much more green, with a more pure and less costly product, something to that effect. There was some big reason why that oil&gas company was so excited about it. If the oil&gas industry incorporates this into their standard processes, with the sheer volume of this fluid they will need every day, that will be HUGE, just that one piece of all this alone. Somewhere in there I thought I remembered that in the process it helped turn sour crude into sweet, just don't recall how specific that point was.

Anyone here remember?

This is so much more than just hospitals and spraying to kill the coronavirus. The agricultural/cannabis industry and oil&gas industry customized trials are going on as well.

And, of course, the UK trials are about to hit (The UK hospital trial already completed, and the 2 university studies are supposed to complete the end of March to first week of April, meaning anytime now). Just waiting on results and orders, both expected to be very favorable.

Long & Strong!

GLTA
========================
J
?
jayashri bhadane

Hypochlorous Acid Market Demand Would Increase Rapidly
Hypochlorous Acid Market: Excellent Microbial and Oxidizing Properties
Hypochlorous acid is a weak acid formed by dissolving chlorine in water. It possesses excellent microbial and oxidizing properties. It is used as a disinfectant agent in medical, water treatment, and food additives in food & beverages industry.
Sodium hypochlorite and calcium hypochlorite are the two types of hypochlorous acid. Sodium hypochlorite is a widely consumed hypochlorous acid. Sodium hypochlorite can be easily stored and transported. It is more effective than chlorine gas in various applications.
Read report Overview@
https://www.transparencymarketresearch.com/hypochlorous-acid-market.html
Hypochlorous acid is employed in various end-user industries such as water treatment, wound management, food & beverages, oil & gas, and personal care. Demand for hypochlorous acid in the wound management segment is projected to rise significantly in the near future. Hypochlorous acid acts as an excellent disinfectant in wound healing applications. It accelerates the healing process of any wound and other infections such as eye infection, ear infection, etc. Hypochlorous acid has excellent disinfectant properties, which help destroy pathogens, bacteria, and fungi.
Request PDF Brochure@
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=68783
Key drivers of Hypochlorous Acid market
Rise in demand for oxidizing and disinfecting agents in order to provide quality water is driving the global hypochlorous acid market.
Hypochlorous acid is highly cost effective. It is non-toxic to humans and animals. Therefore, it is highly preferred in the water treatment industry.
Rise in usage of hypochlorous acid in sterilizing bacterial infection by drying out blood cells is boosting its demand in the medical industry.
Hypochlorous acid is also used as an active sanitizing agent in swimming pools and skin cleansing agent in cosmetic applications.
It is used in the manufacture of calcium hypochlorite (Ca(OCl)2) and sodium hypochlorite (NaOCl), which are further used in the manufacture of disinfectants, bleaches, and deodorants.
Food & Beverage Industry and Wound Management to offer attractive opportunities
Increase in usage of hypochlorous acid in the food & beverages industry is estimated to provide lucrative opportunities to manufacturers of hypochlorous acid in the near future.
Hypochlorous acid is used for cleaning food processing equipment and dish washers. It is also employed as food additive in processing poultry products and seafood products.
Hypochlorous acid is gaining momentum as a potential wound care agent in the pharmaceutical industry. It is a highly effective wound irrigation solution, which is entirely safe for human tissues. It aids in elimination of unpleasant wound odor and removes bacteria from wound surface.
Hypochlorous Acid may form Explosive Gas in Concentrated Form likely to Restrain Market
Hypochlorous acid is highly dangerous and can form explosive gas if used in concentrated form. This is anticipated to restrain the market during the forecast period.
When exposed to air, it disintegrates and causes nausea, abdomen pain, etc. If released in water bodies, hypochlorous acid may harm aquatic animals, thereby adversely affecting biodiversity. These factors are estimated to restrain the demand for hypochlorous acid during the forecast period.
Stuck in a neck-to-neck competition with other brands? Request a custom report on competition on Hypochlorous Acid Market here
Asia Pacific Expected to Hold Leading Share in the Global Hypochlorous Acid Market
In terms of region, the demand for hypochlorous acid can be split across five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
In terms of consumption, Asia Pacific dominated the global hypochlorous acid market in 2018. Developing economies such as China, India, Vietnam, and Indonesia are the leading consumers of hypochlorous acid in Asia Pacific.
Rapid industrialization and increase in demand for sodium hypochlorite in chemical, agriculture, and pharmaceutical industries are anticipated to fuel the hypochlorous acid market during the forecast period.
Demand for hypochlorous acid in countries in Europe such as Germany, France, and the U.K. is projected to increase during the forecast period primarily due to the rise in demand for sodium and calcium hypochlorite in the food & beverages industry in the region.
The U.S. is the leading consumer of hypochlorous acid in North America. Increase in demand for hypochlorous acid in industrial applications such as cooling water treatment is propelling the market in the U.S.
Latin America and Middle East & Africa are highly dependent on hypochlorous acid import. This is likely to hamper the sales of hypochlorous acid in these regions. However, production capacity expansion by various manufacturers in Brazil, Mexico, and GCC is expected to augment the demand for hypochlorous acid in Latin America and Middle East & Africa during the forecast period.
Key Players in Hypochlorous Acid Market:
New product launches and mergers & acquisitions are the key strategies adopted by top players operating in the market. For instance, in 2018, URGO Medical, a leading player in wound care products, entered into an asset purchasing agreement with REALM Therapeutics, a biopharmaceutical company based in the U.S. REALM Therapeutics engages in research activities to discover new hypochlorous acid based treatments for atopic dermatitis and allergic conjunctivitis. This acquisition is expected to help URGO Medical become the leading player in advanced wound care business across the globe.
Key players operating in the global hypochlorous acid market include
Lenntech B.V.
BASF SE
Arkema S.A.
Lonza.
Inovyn Chlorvinyls Limited
Olin Corporation
Nouryon (Previously under Akzo Nobel N.V.'s coating division)
Occidental Petroleum Corporation
Kuehne Company
AGC Chemicals
Surpass Chemical Company, Inc.
Westlake Chemical Corporation
Clorox Company
Tianjin Ruifuxin Chemical
Tosoh Corporation
Aditya Birla Chemicals
Aqualution Systems Ltd
Ultrapure HOCL (Pty) Ltd
Others

===================
Friday, April 3, 2020 10:10:28 AM Cherry
Re: None Post # 80097 of 80187
WHY YOU WANT TO BUY ALL THE PCTL YOU CAN

Right now, IMO, before PCT LTD (ticker PCTL) announces the UK hospital results which might potentially lead to 600+ hospital installations in the UK, before the March 2020 revenues from increased fluid sales are known, before the scientific data on treating disease/mold/fungi in the citrus & cannabis industries is announced, before results from the oil & gas industry testing, and before the delayed 2019 Q3 of which will contain outdated information from over 6 months ago-

People reading here may have read and seen, in bits and pieces, all these things below.

How anyone interprets & verifies anything, and researches further, is up to them. Nothing here is advice.

Since late 2019:
More hospitals,
More distribution,
More geographic regions,
More production capacity,
More sales of the fluid itself & increasing dramatically,
EPA approved on List N to disinfect surfaces for NCOV-19-SARS-2,
Existing clients are buying more systems or extending their contracts,

They have 2 websites:
https://www.para-con.com/

https://pctcorphealth.com/

Social media
https://twitter.com/PCTL2020

https://www.facebook.com/PreventTheSpreadOfInfections/

Videos of some types of applications:
https://youtu.be/Qo6B2pjFBzw

https://youtu.be/bZLjJdqpz9s

https://youtu.be/tMTBcFGxTRk

https://www.linkedin.com/…/alex-guttman-821b506_a-hospital-…

https://www.linkedin.com/…/alex-guttman-821b506_do-our-part…

Quotes:
read comment by Kurt Strauss, NY Presbyterian Hospital, VP Support Services
https://www.linkedin.com/…/jonathan-johonnesson-2981986_hea…

read comment by Greg Baker, Johnston UNC Healthcare, Environmental Services Associate Director
https://www.linkedin.com/p…/ugcPost-6650417189276958720-aiRk

read comment by John Pickett, Memorial Healthcare System, Director EVS
https://www.linkedin.com/…/alex-guttman-821b506_i-just-left…

read comments by Alex Guttman, Ace Janitorial (NY distributor), VP Marketing & Research
https://www.linkedin.com/…/alex-guttman-821b506_i-just-left…

read comment by person connected to UK NHS
https://twitter.com/CharlotteFox…/status/1237415226695389185

Recent news:

Mar 27
PCT LTD Obtains EPA Approval for Emerging Pathogens Labeling for Use Against SARS-CoV-2, the Novel Coronavirus That Causes the Disease COVID-19
http://www.businesswire.com/…/PCT-Obtains-EPA-Approval-Emer…

Mar 25
https://www.businesswire.com/…/PCT-Expands-Production-Capac…

Mar 18
PCT LTD Receives Large Purchase Order for Recurring Sales of Fluids for Non-Medical Use and Explains Current Revenue Streams
https://www.businesswire.com/…/PCT-Receives-Large-Purchase-…

Mar 16 interview
PCT LTD Expands Production Capacity, Accelerates Hypochlorous Acid Production, UK update
https://audioboom.com/…/7532080-pct-ltd-discusses-their-uni…

Mar 13 adds a distributed in Puerto Rico and follow on sales of high volume units
http://www.businesswire.com/…/PCT-Adds-International-Distri…

Mar 11 Adds another NYC hospital
https://www.businesswire.com/news/home/20200311005641/en/

Feb 20 conference call
https://stme.in/tAIWdx33KX

Some of the hospitals they appear to be in:

FL: Memorial Healthcare System
read comment by John Pickett (in replies), Director EVS
"Great product and part of our enhanced disinfectant effort in our ER and public areas today."
https://www.linkedin.com/…/alex-guttman-821b506_i-just-left…
https://www.mhs.net/…/…/memorial-regional-exterior-image.jpg

NC: Johnston UNC Health Care Hospital
?509 N Brightleaf Blvd , Smithfield, NC 27577?
news 5/18/2018 http://tiny.cc/idn9ez
https://www.johnstonhealth.org/…/jh-smithfield-web-652x377.…

NY: Mount Sinai South Nassau
?1 Healthy Way, Oceanside NY 11572?
news 10/4/2019 http://tiny.cc/gen9ez
https://www.mountsinai.org/…/MSHS-Landing-SouthNassau-2col-…

NY: Presbyterian Columbia University Irving Medical Center
?622 W 168th St, New York NY 10032?
news 9/24/2019 http://tiny.cc/44feiz
https://columbiasurgery.org/s…/default/files/location_ph.jpg

NY: Presbyterian Morgan Stanley Children's Hospital
3959 Broadway At, W ?165 St, New York NY 10032?
news 5/6/2019 http://tiny.cc/sfn9ez
https://columbiasurgery.org/…/defa…/files/location_chony.jpg

NY: SUNY Downstate Medical Center, University Hospital of Brooklyn
?450 Clarkson Ave, Brooklyn NY 11203?
news 10/31/2019 http://tiny.cc/onzhfz
https://www.downstate.edu/uhb/_images/uhb-canopy.jpg

NY: Memorial Sloan Kettering Cancer Center
(not confirmed)
?1275 York Avenue New York, NY 10065?
https://www.mskcc.org/…/1125/3x2/092716_msk-00047_ret2_3x2_…

NY: additional NY hospital
news: 03/11/2020 https://www.businesswire.com/…/PCT-Experiencing-Rapid-Incre…

NV: Carson Tahoe Regional Medical Center
?1600 Medical Pkwy, Carson City NV 89703?
news 1/10/2019 http://tiny.cc/8jn9ez
https://www.travelnursesource.com/images/hospitals/5201.jpg

UK: hospital
500 beds http://tiny.cc/u6m9ez
news 10/22/2019 http://tiny.cc/mmn9ez
sales could reach 600+ hospitals in system
https://audioboom.com/…/7532080-pct-ltd-discusses-their-uni…

Some of the distributors, sub registrants, etc:

ABC, Puerto Rico
www.abcmedicalpr.com
(https://apnews.com/Busines…/f5ac60f75c4b407fb7b69ead849905b9)

ACE Janitorial, NY
https://www.acejan.com/#infection-control

Advance Industrial Maintenance, NY
https://www.advanceindustrial.org/
https://www.linkedin.com/…/alex-guttman-821b506_do-our-part…

Bio Blasting, NJ
https://BioBlasting.com

Interior Maintenance Specialists, TX
https://imsdfw.com/
https://www.linkedin.com/…/activity-6651456530740768768-GHv9

Sanitis, TX
https://www.sanitisglobal.com/annihilyzer-room-disinfection…
V
Santa Fe Power, FL
http://www.santafepower.net/healthcare-products.html

===============
Tuesday, 04/07/20 11:13:24 AM
Re: Patience 1 post# 81708
0.005
Post # 81730 of 82300

Quote:

NEWS OUT!! 4/7/20, 9:55 AM LITTLE RIVER, S.C.--(BUSINESS WIRE)


PCT LTD (OTC Pink: PCTL) ("PCTL") is excited to announce they have increased production capacity at their Little River, South Carolina facility.

Updating an earlier release (March 25th), the South Carolina facility is now capable of producing up to 10,000 gallons of fluids per day. A marked increase over earlier capabilities. The company is now better positioned to meet the growing demand for its Hypochlorous Acid-based disinfecting fluids.

“Our team has been working around the clock over the last several weeks to make this happen,” says Stuart Emmons, PCTL Executive VP of Engineering and R & D. “The South Carolina facility is now better positioned to fulfill the daily orders we have been receiving.”

Due in part to the ongoing coronavirus pandemic, the company has seen an exponential increase in sales and inquiries from current and prospective customers. Late last month the company shifted its short-term focus towards fluid production and sales to meet increasing demand.

“It’s supply and demand,” according to PCTL CEO Gary Grieco. “The demand is there and now so is the supply. We needed to shift our focus towards where we can have the most impact and do the most good for our customers and the communities they serve. At the same time, this presents an opportunity for us to elevate our profile, grow our business, and showcase how effective our products can be in the ongoing fight against the spread of infectious disease.”

The company has also been hiring additional support staff to support growing business operations. Most recently, the company engaged Joseph Tippmann, graduate of The University of Michigan’s Industrial Design and Architecture program, as a new design engineer. Tippmann joined the company on a contract basis initially and has spent the past two weeks performing design updates on Annihilyzer and Hydrolyte Rack systems in addition to helping design a more modular system for easier assembly.

Tippmann is also a co-owner of Werks Manufacturing, a Fort Wayne, Indiana based manufacturing company which PCTL engages for the purpose of manufacturing and assembling parts for use in the company’s Annihilyzer® Infection Control System and other systems.

Werks Manufacturing is expanding their operation and will increase parts and assembly production to meet PCTL’s growing demand. In addition, Werks will also serve as a fluid depot for PCTL’s clients in the northern Midwest part of the United States. Werks will initially be capable of producing up to 4,000 gallons per day of disinfecting fluids, including Hydrolyte®, for sale and use by PCTL to clients in Detroit, Chicago, and throughout the region. This fluid production capacity can be increased as needed to serve growing demand.

“We are continuing our rapid growth plans,” says Grieco. “Through strategic partnerships, distribution agreements, and more, we are gaining market share, increasing revenue at a rapid pace, and growing our business both quickly and efficiently.”

Additional News and Corporate Updates:

PCTL would like to warn its stockholders and potential investors that material corporate information regarding sales, areas of business and other corporate updates will only be made through press releases or filings with the SEC. PCTL does not utilize social media, chatrooms or other online sources to disclose material information. The public should only rely on official press releases and corporate filings for accurate and up to date information regarding PCTL.
====================

Wednesday, April 8, 2020 1:22:30 PM Beer money
Re: None Post # 82319 of 82350
Yes Gary Grieco, PCTL CEO, stated, "As a result of the capabilities and benefits of our products, many companies and municipalities across a variety of industries and geographic locations are engaging in intense discussions with PCT LTD."

03/11/2020
https://www.otcmarkets.com/stock/PCTL/news/story?e&id=1551496

PCTL "The 800 pound gorilla, Corona-virus, that has opened up a huge opportunity for us and I can not say any more than that we have been contacted by, and are actively negotiating to address the problem with both companies and government officials and I can not say more than that."

Gary Geico, CEO
March 16th, 2020

To hear Gary Grieco’s entire interview, follow the link to the podcast here:
https://audioboom.com/posts/7532080-pct-ltd-discusses-their-unique-annihilyzer-disinfectingsystem-and-impact-of-the-coronavirus-wit

In addition, Grieco further commented, "All of our hospital customers using our infection control system and disinfectant are utilizing the systems as a front-line defense throughout their facilities, including in all public area such as restrooms, lobbies, waiting rooms, elevators, corridors, cafeterias, etc. all throughout the day and night and in the presence of patients, staff and visitors."

Gary Grieco’s entire interview link here:

https://www.para-con.com/images/docs/PCTL03-16-20.pdf

============
Thursday, April 9, 2020 10:01:52 AM
Re: None Post # 82599 of 82789
Hypochlorous Acid Okay For Easter Eggs
Hypochlorous acid is cleared by the FDA for use on meat, poultry, fish & seafood, fruits & vegetables and shell eggs as a no-rinse sanitizer.
FCN 1811 is a Food Contact Notification (FCN) from the FDA for using electrolytically generated hypochlorous acid as an antimicrobial agent in an aqueous solution in the production and preparation of whole or cut meat and poultry; processed and preformed meat and poultry; fish and seafood; fruits and vegetables; and shell eggs.
To read more about food contact notification 1811, visit the FDA website in the link below.
https://www.hypochlorousacid.com/regulation
[Suppressed Image]

==================
Thursday, April 9, 2020 10:35:37 AM
Re: None Post # 82670 of 82807
Why the NHS and Private Clinics Should Look Further than Alcohol-Based Sanitisers
The CoViD-19 pandemic has brought alcohol to the fore; whether it is the amount the British public is consuming to get through self-isolation or the level required in hand sanitiser to make it effective, the news stories are everywhere.
Many of these revolving around the shortage of traditional alcohol-based hand sanitisers and how prices are soaring. With this being the case, why then don’t the NHS and other health care facilities look elsewhere? Is there no other option?
In fact, there is another option which is rapidly emerging as the new go-to sanitiser during the CoViD-19 pandemic; Hypochlorous Acid (HOCl).
What is Hypochlorous Acid?
HOCI is generated when white blood cells attack harmful bacteria and is harmless to the human body. In December 2019 Optometry Times published an article on HOCl and they explain it much better than I can… “HOCl is a weak acid that occurs naturally in our body. Neutrophils are white blood cells that are the first to arrive on site when an invading pathogen is detected. Neutrophils will chase down and engulf the pathogen through phagocytosis. Upon contact, neutrophils release a burst of bactericidal chemicals including its most powerful oxidizing agent, HOCl. This kills the pathogen by tearing down the cell membranes and proteins”.
Optometry Times called HOCl “the perfect weapon to fight germs. It hits hard against pathogens like Methicillin-Resistant Staphylococcus Aureus (MRSA) and Pseudomonas Aeroginosa. Yet this powerful weapon is 100 percent safe for humans, chemical free, non-toxic and all-natural”.
Due to these attributes HOCl is being widely used in South Korea in their battle against CoViD-19, disinfecting everything from food to people to hospital wards and their mass transit systems. Looking at the way in which they have taken control of the spread of the virus it is clear to see that HOCl can also help the United Kingdom to gain the upper hand in this struggle.
https://www.belle.org.uk/news-1/2020/4/2/why-the-nhs-and-private-clinics-should-look-to-hypochlorous-acid-rather-than-alcohol-based-sanitisers

=============

beer$$money ? 


Sunday, April 12, 2020 8:04:27 PM
Re: BIGBUCKS post# 83703


Post # 83709 of 83745 
Alex Guttman Author> Huge interest being developed on LinkedIN
VP marketing and Research at Ace Janitorial, Sales Mgr Escalator Cleaning company, Senior VP HAI Consultants

Randy Stiles can't mention names without permission but I can say that most of the major healthcare systems in NYC are now using our system

Randy Stiles +Executive Account Manager at Paylidify

Jon Pickett, MBA is this being used at all Memorial Healthcare Locations? The feedback on the system has been great.


Jody Read
CEO at PCT Health, PCT LTD

Glad to see that the efforts of the entire team at ACE and PCT to bring this system to market has been a success and we are looking forward to placing these systems into every hospital, surgical center, nursing homes, and long-term care facilities!


Mansour N Elchammaa
Advisor, consultent, restaurants franchises,Tourism,Real estate,stocks .EX founder pita NUTSY/O restaurants.

Good am Mr Jody.could I represent your company in Dubai.? Tnx

Fritz Oehler
Executive Director at Sprenger Health Care Systems
Looks like this product could be an answer to many infection control issues in our industry.


https://www.linkedin.com/posts/alex-guttman-821b506_i-just-left-mount-sinai-south-nassau-system-activity-6644264439115763712-vN4T/

=============

Evaluate ? 

Sunday, April 12, 2020 8:53:14 PM
Re: BIGBUCKS post# 83629

Post # 83715 of 83745 
Some additional DD. The full section in that recent PCTL release includes:
Quote:

The company has also been hiring additional support staff to support growing business operations. Most recently, the company engaged Joseph Tippmann, graduate of The University of Michigan’s Industrial Design and Architecture program, as a new design engineer. Tippmann joined the company on a contract basis initially and has spent the past two weeks performing design updates on Annihilyzer and Hydrolyte Rack systems in addition to helping design a more modular system for easier assembly.
Tippmann is also a co-owner of Werks Manufacturing, a Fort Wayne, Indiana based manufacturing company which PCTL engages for the purpose of manufacturing and assembling parts for use in the company’s Annihilyzer® Infection Control System and other systems.
Werks Manufacturing is expanding their operation and will increase parts and assembly production to meet PCTL’s growing demand. In addition, Werks will also serve as a fluid depot for PCTL’s clients in the northern Midwest part of the United States. Werks will initially be capable of producing up to 4,000 gallons per day of disinfecting fluids, including Hydrolyte®, for sale and use by PCTL to clients in Detroit, Chicago, and throughout the region. This fluid production capacity can be increased as needed to serve growing demand.


I could not find much on google in regards to Joseph Tippmann.
I did find Werks Manufacturing Inc. = http://werksmfg.com ;;... but ... website is “under construction”.
It appears to be located at 2300 Meyer Road Fort Wayne, IN 46803.
It appears the phone number might be [phone].
Also at this address appears to be: Advanced Media Integration LLC = Video production service = Vincent P Tippmann. same phone number?

I did also find Vincent P. Tippmann at this website: https://vptag.com/
Tippmann Affiliated Group is a family owned organization with a diversified group of business segments throughout North America and around the world. Approaching a half-century in business, Tippmann Affiliated Group businesses hold 17 patents and numerous product and service awards in various industries, including Automotive, Food Service, Refrigeration, Medical Device and Transportation. As it stands today, Tippmann Affiliated Group remains a family owned organization with a diversified group of business segments throughout North America and around the world. Headquartered in Fort Wayne, IN, Tippmann Affiliated Group operates its main campus on 75 acres and 810,000 sq/ft. of manufacturing and office space. 4410 New Haven Ave Fort Wayne, IN 46803. Phone:[phone].
It appears that 2300 Meyer Road Fort Wayne, IN 46803 is immediately adjacent to 4410 New Haven Ave Fort Wayne, IN 46803. Father & son? Could Vincent Tippman be the co-owner of Werks Manufacturing (together with Joseph Tippmann?

=====================

Ronin Wednesday, 04/15/20 10:42:51 AM
Re: TKane post# 86153
Post # 86171 of 86190

News hit DOW JONES and BUSINESS wire! Lots of eyes on this now!

https://www.businesswire.com/news/home/20200415005407/en/PCT-Reports-Q3-2019-Financials-Revenue-Increases

https://finance.yahoo.com/news/pct-ltd-reports-q3-2019-130800993.html

https://www.wallstreet-online.de/nachricht/12406105-pct-ltd-reports-q3-2019-financials-revenue-increases-435-operating-expenses-decrease

=======================

Evaluate  Wednesday, April 15, 2020 3:12:04 PM
Re: Evaluate post# 86473 Post # 86479 of 86491
https://pureandclean.us/disinfectant-sanitizer-gallon/
It appears that Pure & Clean is a distributor for PCT's HOCl, at 460 PPM, since their web page shows it is a distributor of EPA Reg. No. 92108-1.
Only available in the following states: Florida, Kansas Maryland, Missouri, Nevada, Oklahoma and Texas. For all other states, please order the Surface Cleaner Pro products: https://pureandclean.us/surface-cleanser-pro/ Pure&Clean Disinfectant/Sanitizer?
460 ppm HOCl. This is a New Generation Disinfectant formulated using Hypochlorous Acid (HOCl) that cleans, deodorizes, and disinfects. As a distributor of EPA Reg. No. 92108-1, the product pure&clean™ (EPA Reg. No. 92108-1-88098) is included on the list of products approved by the US

=====================

BIGBUCKS  Wednesday, April 15, 2020 3:09:42 PM
Re: None Post # 86478 of 86491
PCT LTD Reports Q3 2019 Financials; Revenue Increases 435%, Operating Expenses Decrease

https://www.businesswire.com/news/home/20200415005407/en/PCT-Reports-Q3-2019-Financials-Revenue-Increases

===============

Re: BRITT2575 post# 86776
0.500
Post # 86946 of 86994

Quote:

ANOTHER NEWS COVERAGE TONIGHT ON PCTL VIDEO #2

https://www.myrtlebeachonline.com/latest-news/article242029616.html

At 0’37: it shows that the “Annihilyzer is “Presented By: Annihilare and Paradigm Convergence Technology Corp”
I was surprised to see this.
Question: Does Annihilare also share in the revenues/profits of selling/leasing Annihilyzers?

Perhaps related to the patent on the RFID?

=====================

Q & A

Home - HypochlorousAcid.com

https://www.hypochlorousacid.com/faq/hocl-faq

==================

governors email addresses

 https://www.nga.org/governors/addresses/

===========
BRITT2575 ? 
Friday, 04/17/20 12:41:50 AM
Re: None
?
0
Post # 88648 of 88658 

PCT EUROPE LTD SIGNS DISTRIBUTION AGREEMENT WITH UK NHS COMPANY, RECEIVES ADDITIONAL NYC HOSPITAL ORDER
April 17 2020 - 12:08AM
InvestorsHub NewsWire Print
PCT EUROPE LTD SIGNS DISTRIBUTION AGREEMENT WITH UK NHS COMPANY, RECEIVES ADDITIONAL NYC HOSPITAL ORDER

Little River, SC -- April 17, 2020 -- InvestorsHub NewsWire -- PCT LTD (OTC Pink: PCTL) is pleased to announce new growth and expansion activities in the UK and NYC. PCT Europe Ltd, the UK-based partner of PCTL is pleased to announce they have signed an exclusive trading partnership/distributor agreement with an NHS (U.K. National Health Service) company.

In tandem with PCT Europe Ltd, the UK NHS company will introduce PCT technology to each NHS Hospital Trust with the intention of them rolling out PCT's unique technology and system throughout the health services 233 Trusts comprising over 600 hospitals. In addition, approximately 14,000 Care Homes in the U.K. will also be introduced to PCT's technology. A steady flow of orders is expected to commence throughout the remainder of 2020 and into 2021.

The first PCT system has now been installed in a large NHS hospital in the north of England. This system is expected to enter clinical service early in May once the final series of biological tests of the PCT hospital disinfectant solution have been completed. Results of these tests have so far demonstrated that the PCT disinfectant has met or exceeded its ability to kill the range of pathogens previously achieved during EPA tests in the United States.

"We couldn't be happier with the results thus far in our UK trials and are delighted with the progress our UK partner is making. This arrangement will introduce our system to thousands of hospitals and healthcare facilities," says PCTL CEO Gary Grieco. "At the same time, the reality of the current healthcare crisis both domestically and abroad is sobering. We're thrilled to be able to grow our business but nevertheless remain focused on our core mission which from day one has always been helping people."

The company continues to expand domestically as well. Following an earlier release dated April 14th, the company is also announcing an additional purchase order for PCT Corp.'s Annihilyzer® Infection Control Systems in New York City.

The order comes from a large NYC hospital with a current bed count in excess of 2,500. Installation will be made in coordination with PCT Corp's primary healthcare distributor, ACE Janitorial Services.

"With three PO's for our infection control system this week and more on the way, we continue to make strides both in growing our business as well as our goal of helping our clients fight the spread of infectious diseases," says Grieco. "We are on pace for unprecedented and record growth in all areas of our business."

Additional News and Corporate Updates:

PCTL would like to warn its stockholders and potential investors that material corporate information regarding sales, areas of business and other corporate updates will only be made through press releases or filings with the SEC. PCTL does not utilize social media, chatrooms or other online sources to disclose material information. The public should only rely on official press releases and corporate filings for accurate and up to date information regarding PCTL.

========================

Details for EXCELYTE VET
*
EPA Contract Info
EPA Contact Information

https://iaspub.epa.gov/apex/pesticides/f?p=PPLS:8:::NO::P8_PUID,P8_RINUM:513158,92108-1

==============================

PM
Re: None Post # 92362 of 92385
PCTL> UK NHS is the largest single healthcare delivery organisation in the world.

SELLING TO THE NHS


SUMMARY
This guide outlines the structures that exist to help companies contact and sell existing and innovative products into the NHS, a huge organisation which can appear very complex.

IN BRIEF
NHS Supply Chain
Procurement routes – national, regional and local contracts

Products for GP prescription

Estates – capital equipment

Innovation – new products



The NHS is the largest single healthcare delivery organisation in the world. It constitutes a major opportunity for UK medical device companies. NHS trusts can purchase products through one of five main routes:

Directly from suppliers using National Framework Contracts

From the NHS Supply Chain which provides end-to-end supply chain services incorporating procurement, logistics, e-commerce and customer and supplier support

Collaborative Procurement Hubs/Confederations (regional multi-trust purchasing)

Local contracts managed by individual trusts

Pan-government National Framework Contracts

NHS SUPPLY CHAIN

The NHS Supply Chain is a single organisation created for the benefit of NHS trusts, hospitals and other healthcare organisations. The organisation combines the former NHS Logistics Authority, significant parts of the NHS Purchasing and Supply Agency, expertise in healthcare logistics from DHL and procurement experience from Novation.


PROCUREMENT ROUTES
National contracts Tenders: Contracts for products and services valued at over £90,319 (01 Jan 2008) must be advertised in the Supplement to the daily Official Journal of the European Union (OJEU). Procurement levels change, but you can confirm the current level by visiting: http://www.ojec.com.

NHS-sid: This is the official NHS supplier information database on which companies can enter their information for free:

http://www.sid4health.nhs.uk. It rationalises the management of pre-qualification data during the procurement process and can only be fully accessed by authorised NHS personnel. Suppliers looking to compete for advertised NHS contracts must still submit applications in the required format. Any supplier is free to register its services on NHS-sid.
The information published is made freely available to NHS users. Registering on this system does not imply that a supplier has any special or ‘approved’ status. Regional contracts Collaborative organisations: Most NHS trusts are now partners in ‘collaborative procurement organisations’ where, normally on a regional basis, they can share information and resources to achieve economies of scale.

Local contracts Individual trust contracts: Local contracts are often managed by a trust’s supplies department. Its approach to suppliers will vary according to the value, size and complexity of its requirements. DH has set down procurement guidelines indicating that for contracts valued below £3,000 a trust should ask for telephone quotes; for contracts valued between £3,000 and £10,000, it should request a minimum of three written quotes; for contracts valued above £10,000, a minimum of three formal written tenders should be sought. Actual interpretations of these guidelines vary from trust to trust.

PRODUCTS FOR GP PRESCRIPTION

Suppliers wishing to list their products under the Drug Tariff for prescription by GPs or nurses must seek approval from the NHS Business Service Authority (NHSBSA). These will usually be products for self-administration, possibly with a carer’s help, and will normally fall into the following categories: dressings, bandage and associated appliances, incontinence appliances, stoma appliances, and chemical reagents. If the NHSBSA grant approval, the cost, either comparatively with other similar products, or, if it is a new treatment regime, by comparison with alternatives, will be reimbursed. You can access the application form at: www.nhsbsa.nhs.uk.

ESTATES – CAPITAL EQUIPMENT

DH uses two major Public and Private Partnerships (PPPs) to deliver its NHS Plan: the Private Finance Initiative (PFI) and NHS Local Improvement Finance Trust (LIFT). The NHS ProCure 21 Framework brings the NHS and the construction industry together for new-build projects. You can find information on PPPs and associated procurement policies at: www.dh.gov.uk.

INNOVATION – NEW PRODUCTS

The procurement routes above apply to established products. If you are a supplier of innovative products, you should be aware of the organisations involved in product approval:

The UK Medicines and Healthcare product Regulatory Agency (MHRA) This is the government agency responsible for ensuring that medicines and medical devices work and are safe.

Regulatory affairs: Medical devices can only be placed on the market in the UK/EU if they are certified safe, are of the required quality to fulfill the manufacturer’s ‘intended purpose’ and comply with the appropriate Medical Device Directive (CE marking). The MHRA audits the performance of manufacturers and notifies bodies responsible for granting CE marks. You can find more details at: www.mhra.gov.uk.

Clinical trials: The MHRA approves clinical trials/investigations and provides guidance for manufacturers. To obtain a CE mark, a manufacturer must show that the device complies with the relevant ‘Essential Requirements’ of the appropriate Medical Device Directive. In some instances, a clinical investigation will be required. The MHRA website (listed above) provides guidance on this issue.

Small Business Research Initiative (SBRI): The new SBRI is a cross-government programme for the procurement of technology development projects, including the demonstration and evaluation of new technologies. DH has run a pilot SBRI competition in Healthcare Associated Infections in conjunction with the Technology Strategy Board. The benefit to the Department and the NHS is to make new developments available faster and more effectively. National Institute for Health and Clinical Excellence (NICE) NICE (www.nice.org.uk) is responsible for providing national guidance on the promotion of good health and the prevention and treatment of ill health. Its activities include:

Technology appraisals – Recommendations on the use of new and existing medicines and treatments within the NHS, based upon a review of clinical and economic evidence
Interventional procedure guidance – Many of the procedures that NICE investigates are new, but it also looks at more established procedures if there is uncertainty about their safety or how well they work

NHS National Innovation Centre (NIC): NIC determines the need for innovative products, particularly in the development stage, and speeds up the development and adoption of those that deliver the best results for patients. It provides a point of entry to innovators of healthcare technology via its website and through a web-based assessment process. By considering ideas and products at every stage, it can direct them to the most.

http://knowledge.nic.nhs.uk/documentDetails.aspx?docId=10